New long-term data show SHINGRIX continues to provide high ... - GSK
WEBApr 17, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive data from the ZOSTER-049 long-term follow-up phase III trial which followed participants for up to approximately 11 years following initial vaccination with SHINGRIX (Recombinant Zoster Vaccine or RZV).
GSK Announces Positive Topline Data on Co-Administration of …
WEB2 days ago · PHILADELPHIA, September 18, 2024--GSK announces positive topline data on co-administration of AREXVY and SHINGRIX
GSK announces positive topline data on co-administration of …
WEB2 days ago · GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) when co-administered with SHINGRIX (Zoster Vaccine Recombinant, …
New data show Shingrix can provide at least 10 years of ... - GSK
WEBOct 19, 2022 · GSK plc (LSE/NYSE: GSK) today announced positive interim results from the ZOSTER-049 extension study showing that overall Shingrix (Zoster Vaccine Recombinant, Adjuvanted) can provide at least a decade of protection against shingles (herpes zoster) after initial vaccination.
GSK's Respiratory Syncytial Virus Vaccine Given Together With …
WEB2 days ago · Wednesday, GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy (Respiratory Syncytial ...
New Shingrix data demonstrate 100% vaccine efficacy in the ... - GSK
WEBAug 23, 2023 · GSK plc (LSE/NYSE: GSK) today announced positive results from the first-ever efficacy trial of Shingrix (Recombinant Zoster Vaccine or RZV) in China. These results come from the post-license phase IV trial (ZOSTER-076), which evaluated the efficacy and safety of RZV in preventing shingles in adults aged 50 and over.
Shingrix approved in the US for prevention of shingles in ... - GSK
WEBJul 26, 2021 · GlaxoSmithKline plc today announced that the US Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 18 years and older who are or who will be at increased risk of shingles due to immunodeficiency or immunosuppression caused …
GSK Announces Positive Topline Data on Co-Administration of
WEB2 days ago · PHILADELPHIA-- (BUSINESS WIRE)-- #Adult --GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) when co-administered with SHINGRIX (Zoster Vaccine Recombinant ...
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
WEB1 day ago · ILMN. BVS. GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in ...
GSK says efficacy of its shingles vaccine remains high after years
WEBApr 17, 2024 · British drugmaker GSK said on Wednesday long-term data showed that its blockbuster shingles vaccine, Shingrix, had 79.7% efficacy in participants aged 50 years and above, six to 11 years...